U.S. Trial of AstraZeneca COVID-19 Vaccine May Resume This Week - COVID-19 Clinical Trial
Breaking News | COVID-19

U.S. Trial of AstraZeneca COVID-19 Vaccine May Resume This Week

AstraZeneca Plc’s AZN.L COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness in a study participant, four sources told Reuters. AstraZeneca’s large, late-stage U.S. trial has been on hold since Sept. 6, after a participant in the company’s UK trial fell ill with what was suspected to be a rare spinal inflammatory disorder called transverse myelitis.

The sources, who were briefed on the matter but asked to remain anonymous, said they have been told the trial could resume later this week. It was unclear how the FDA would characterize the illness, they said. An FDA spokeswoman declined to comment. The agency is requiring researchers conducting the trial to add information about the incident to consent forms signed by study participants, according to one of the sources.


Sinopharm Able to Make Over 1 Billion Coronavirus Vaccine Doses in 2021

China National Pharmaceutical Group (Sinopharm), one of several Chinese firms developing coronavirus vaccines, said it may have the capacity to produce more than 1 billion doses in 2021, Chairman Liu Jingzhen said on Tuesday.

About 60,000 people have received Chinese coronavirus vaccine candidates during Phase III clinical trials, with no serious side effects reported so far, Tian Baoguo, an official at China’s Ministry of Science and Technology, said at the same government media briefing.In addition, hundreds of thousands of people in China have been given experimental trial-stage vaccines as part of an emergency inoculation programme launched in July.

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.